Bio-Rad Laboratories, Inc.
NYSE:BIOMedical - Devices
-$0.65 today
- Market cap
- $9.95B
- Beta
- 1.08
- P/E (TTM)
- 45.4
- EPS (TTM)
- $6.26
Volume 0.46M
Average 0.38M
BIO Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Bio-Rad Laboratories, Inc.NYSE: BIO
Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026
Depreciation & amortization remains negative
Q2 FY2026 depreciation & amortization was $0, compared with $40.6M a year earlier. Trailing-twelve-month depreciation & amortization was $127.6M. Over 3 fiscal years it compounded at +6.4% a year.
Context
- Depreciation & amortization amounted to 6.4% of revenue in FY2025, up 0.5 pp from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly depreciation & amortization holds near $0 or moves back toward the trailing-twelve-month quarterly average of $31.9M.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 165.4M USD
- Year-over-year change
- +9.1%
- 4-year CAGR
- +4.7%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 165.4M | +9.1% |
| FY2024 | 2024-12-31 | 151.6M | +3.9% |
| FY2023 | 2023-12-31 | 145.9M | +6.3% |
| FY2022 | 2022-12-31 | 137.3M | -0.2% |
| FY2021 | 2021-12-31 | 137.6M | — |
Depreciation & Amortization vs competitors
How BIO compares with its peers on the latest reported figures
- BIO's LTM Jun 2026 depreciation & amortization of $127.6M is the 5th highest of the 11 companies compared; the peer median is $97.03M.
- Its year-over-year change of -23.5% is the 9th highest of 11, against a peer median of -8.2%.
- Depreciation & amortization amounts to 4.9% of revenue for BIO, versus a peer median of 8.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $2.28B | -18.3% | -6.3% | 4.8% | |
| LTM Sep 2026 | $1.91B | -21.1% | +4.7% | 7.5% | |
| LTM Jul 2026 | $412.24M | -0.2% | -1.7% | 14.2% | |
| LTM Jun 2026 | $230.1M | +9.4% | +35.4% | 6.6% | |
| LTM Jun 2026 | $127.6M | -23.5% | +6.4% | 4.9% | |
| LTM Jun 2026 | $97.31M | -7.0% | +19.4% | 12.4% | |
| LTM Sep 2026 | $96.75M | -8.8% | -3.2% | 7.9% | |
| LTM Jun 2026 | $56.96M | -3.2% | +16.6% | 27.3% | |
| LTM Sep 2026 | $56.52M | -7.7% | — | 9.1% | |
| LTM Mar 2026 | $17.69M | -95.7% | +207.8% | 11.1% | |
| LTM Mar 2026 | $6.29M | -60.3% | -22.5% | 7.3% | |
| Peer median (excluding BIO) | $97.03M | -8.2% | +4.7% | 8.5% | |
Competitors are the stored peer set for BIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2.92B | 2.8B | 2.67B | 2.57B | 2.58B |
| Cost of Revenue | 1.28B | 1.23B | 1.24B | 1.19B | 1.24B |
| Gross Profit | 1.64B | 1.57B | 1.43B | 1.38B | 1.34B |
| Gross Margin | 56.1% | 55.9% | 53.4% | 53.7% | 52.0% |
| Research & Development | 260.64M | 256.89M | 247.43M | 295.9M | 256.9M |
| Selling, General & Admin | 877.12M | 827.83M | 841.7M | 814M | 819.9M |
| Operating Expenses | 1.14B | 1.08B | 1.09B | 1.11B | 1.08B |
| Depreciation & Amortization | 137.6M | 137.3M | 145.9M | 151.6M | 165.4M |
| EBITDA | 5.59B | (4.53B) | (654.8M) | (2.14B) | 1.21B |
| EBITDA Margin | 191.2% | -161.6% | -24.5% | -83.5% | 46.8% |
| Operating Income | 500.34M | 482.62M | 337.8M | 269M | 270.5M |
| Operating Margin | 17.1% | 17.2% | 12.6% | 10.5% | 10.5% |
| Interest Income | 18.9M | 58M | 100.9M | 82M | 95.5M |
| Interest Expense | 1.55M | 38.11M | 49.44M | 48.9M | 49M |
| Other Income / Expenses | 4.95B | (5.19B) | (1.19B) | (2.61B) | 725M |
| Income Before Tax | 5.45B | (4.7B) | (850.1M) | (2.34B) | 995.5M |
| Pre-Tax Margin | 186.4% | -167.9% | -31.8% | -91.3% | 38.5% |
| Income Tax Expense | 1.19B | (1.08B) | (212.78M) | (498.3M) | 235.6M |
| Net Income | 4.25B | (3.63B) | (637.32M) | (1.84B) | 759.9M |
| Net Margin | 145.6% | -129.5% | -23.9% | -71.9% | 29.4% |
| EPS (Basic) | 142.61 | (121.79) | (21.82) | (65.36) | 27.87 |
| EPS (Diluted) | 140.83 | (121.79) | (21.82) | (65.36) | 27.87 |
| Weighted Avg Shares | 29.83M | 29.79M | 29.21M | 28.21M | 27.26M |
| Weighted Avg Shares (Diluted) | 30.21M | 29.79M | 29.21M | 28.21M | 27.28M |
Bio-Rad Laboratories, Inc.
NYSE:BIO
Intrinsic Alpha fair value
Locked
Current Price
$370.17
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.